Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 9,516 matching trials from the live ClinicalTrials.gov search.
Filters: Birmingham, Alabama Clear all
Not listed Phase 3 Interventional

A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients

NCT02605434
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Accordion Pill™ Carbidopa/Levodopa, Sinemet®, Placebo -AP-CD/LD, Placebo- Sinemet
Drug
Lead sponsor
Intec Pharma Ltd.
Industry
Eligibility
30 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Approved Contact Lenses

NCT02699593
View directory record Official record
Conditions
Visual Acuity
Interventions
Test Contact Lens, Control Contact Lens
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
7
States / cities
Birmingham, Alabama • Jacksonville, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Results available

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

NCT02100514
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615; RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
108
States / cities
Alexander City, Alabama • Auburn, Alabama • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 22, 2026, 2:43 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

NCT07321652
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions
Zanubrutinib, Sonrotoclax, Computed Tomography, Bone Marrow Aspiration, Biospecimen Collection, Survey Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
224
States / cities
Birmingham, Alabama • Anaheim, California • Baldwin Park, California + 180 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 2:43 PM EDT
Completed No phase listed Observational

Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs)

NCT00119834
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive
Interventions
Mechanical Circulatory Support Device (MCSD)
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Day and older
Enrollment
23,472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Not applicable Interventional

Use of Formula Fortified With DHA in Infants With Cystic Fibrosis

NCT00530244
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Docosahexaenoic acid (DHA), Standard formula (Enfamil)
Dietary Supplement
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Up to 56 Days
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Atlanta, Georgia • Des Moines, Iowa + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease

NCT00002244
View directory record Official record
Conditions
HIV Infections
Interventions
WF10
Drug
Lead sponsor
OXO Chemie
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 2:43 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

NCT06544733
View directory record Official record
Conditions
HIV-1-Infection
Interventions
Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
35
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 22, 2026, 2:43 PM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

NCT06602479
View directory record Official record
Conditions
Migraine
Interventions
MEDI0618, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 70 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 22, 2026, 2:43 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

NCT03898479
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

RDEA3170 Monotherapy in Subjects With Gout

NCT01927198
View directory record Official record
Conditions
Gout
Interventions
Placebo, RDEA3170 5 mg, RDEA3170 10 mg, RDEA3170 12.5 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
49
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 22, 2026, 2:43 PM EDT
Completed No phase listed Observational

Micra AV Transcatheter Pacing System Post-Approval Registry

NCT04253184
View directory record Official record
Conditions
Bradycardia
Interventions
Micra AV Transcatheter Pacing System
Device
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Rancho Mirage, California • Redwood City, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use

NCT02033109
View directory record Official record
Conditions
HIV
Interventions
PC-1005, HEC gel
Drug
Lead sponsor
Population Council
Other
Eligibility
19 Years to 49 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Early Phase 1 Interventional Results available

TOPIC Trial for COPD

NCT02135432
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Not applicable Interventional

Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs

NCT00050921
View directory record Official record
Conditions
HIV Infections
Interventions
somatropin, Hepatitis A virus, inactivated, Keyhole-Limpet Hemocyanin
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 2:43 PM EDT
Terminated Phase 4 Interventional Results available

Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

NCT01543204
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 22, 2026, 2:43 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

NCT07000084
View directory record Official record
Conditions
Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
BCG Solution, Biopsy of Bladder, Cystoscopy, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Transurethral Resection of Bladder Tumor, Gemcitabine
Biological · Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 2:43 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis (SPMS)
Interventions
Remibrutinib (blinded), Placebo, Remibrutinib (Open label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

NCT01519804
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Placebo, cisplatin/carboplatin, onartuzumab, paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
34
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Not applicable Interventional Results available

The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE Trial

NCT01166347
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
HeartWare® VAS, Control LVAD
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Study of Ruxolitinib in Pancreatic Cancer Patients

NCT01423604
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Ruxolitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
39
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Burbank, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site From an Autograft in the Knee.

NCT00821873
View directory record Official record
Conditions
Knee Injury
Interventions
CR Plug
Other
Lead sponsor
RTI Surgical
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Birmingham, Alabama • Phoenix, Arizona • Englewood, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2013 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

A Study in Recurrent Glioblastoma (GB)

NCT01582269
View directory record Official record
Conditions
Glioblastoma
Interventions
Galunisertib, Lomustine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

NCT02608502
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV-F Vaccine, Phosphate Buffer Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
11,850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
60
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 22, 2026, 2:43 PM EDT